A Phase 1/2, Placebo-Controlled, Randomized, Observer-Blind, Dose-Finding, First-in-Human Study to Describe the Safety, Tolerability, and Immunogenicity of a Respiratory Syncytial Virus (RSV) Vaccine in Healthy Adults
Phase of Trial: Phase I/II
Latest Information Update: 25 Jun 2018
At a glance
- Drugs Respiratory syncytial virus vaccine (Primary) ; Influenza virus vaccine
- Indications Respiratory syncytial virus infections
- Focus Adverse reactions; First in man
- Sponsors Pfizer
- 14 Jun 2018 Planned End Date changed from 4 Dec 2019 to 30 Oct 2019.
- 14 Jun 2018 Planned primary completion date changed from 4 Dec 2019 to 30 Oct 2019.
- 23 May 2018 New trial record